BioMarin Reports Record Q3 Revenue Growth and Projects $3.8B-$3.9B for 2026
BioMarin Pharmaceutical Inc. (BMRN) achieved a significant milestone in the third quarter, surpassing $1 billion in quarterly revenue for the first time. This performance represents a 32% year-over-year increase, driven by strong demand across the company's diversified portfolio of innovative therapies. Looking ahead to 2026, management has provided revenue guidance in the range of $3.8 billion to $3.9 billion. However, the company noted a headwind regarding $70 million in order deferrals, which may impact immediate short-term timing despite the overall positive growth trajectory.
Tickers: $BMRN
Topics: earnings report quarterly results revenue growth
Read the full article at Seeking Alpha
Part of the story Loomis Reports Record Revenue and Operating Margins for Q3 2026 (40 articles)